Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 2, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1756-8722-2-22
Keywords
-
Categories
Funding
- International Scholar Exchange Foundation
- New York Medical College
Ask authors/readers for more resources
DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available